Melanotan I (Afamelanotide): The Only Approved Melanotan
The only melanotan with FDA approval — cleared as Scenesse in 2019 for a rare disorder where sunlight causes severe skin pain, not for general tanning.
What is Melanotan I (Afamelanotide)?
Melanotan I (afamelanotide) is an alpha-MSH analog that, unlike Melanotan II, targets only the MC1R (melanocortin-1) pigment receptor — which is why it lacks the libido and appetite effects seen with Melanotan II's broader receptor activity. It's the only compound in the melanotan family with real FDA approval: cleared in 2019 under the brand Scenesse as a subcutaneous implant for erythropoietic protoporphyria (EPP), a rare disorder in which sunlight exposure causes severe skin pain. A 2015 vitiligo trial also showed it improved repigmentation when combined with phototherapy. That approval is narrow — using it for general tanning or cosmetic purposes sits outside what was actually tested and approved.
Quick facts
- Half-Life
- ~30-50 minutes
- Class
- Alpha-MSH analog, selective MC1R agonist
- Brand Names
- Scenesse (FDA-approved implant for EPP)
- Legal Status
- FDA-approved (Scenesse) for erythropoietic protoporphyria specifically. General tanning/cosmetic use is off-label/unapproved — sold RUO in that context
- Category
- Skin & Aesthetics
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
Research-vendor convention: 10mg vial reconstituted with 2mL bacteriostatic water. The FDA-approved Scenesse product is a subcutaneous implant, not an injectable vial. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Photoprotection / Skin Pigmentation | Bgrade | FDA-approved (Scenesse, 2019) for EPP; a 2015 vitiligo trial (n=55) also showed benefit added to phototherapy. |
Melanotan I (Afamelanotide) Mechanism of Action
Selective MC1R Activation
Melanotan I (afamelanotide) activates only the MC1R (melanocortin-1 receptor), the pigment-specific receptor that drives melanin production in skin. This is the key structural/functional difference from Melanotan II, which activates MC1R alongside MC3R and MC4R — receptors responsible for appetite and sexual-arousal effects. By targeting MC1R alone, afamelanotide produces skin darkening and photoprotection without those broader systemic effects.
Photoprotection Mechanism
Increased melanin production provides genuine photoprotective benefit by absorbing and dissipating UV and visible-light energy before it damages skin cells — the basis for its approved use in erythropoietic protoporphyria (EPP), where accumulated porphyrins make even normal light exposure intensely painful.
Melanotan I (Afamelanotide) Dosage and Protocols
Approved Implant vs. Research Vial
The FDA-approved Scenesse product is a 16mg subcutaneous implant administered roughly monthly by a healthcare provider. Research-vendor vials are commonly reconstituted and dosed in smaller increments (research-typical protocols vary considerably) — this does not replicate the approved implant's controlled, sustained-release delivery.
Melanotan I (Afamelanotide) Side Effects and Safety
Milder Profile Than Melanotan II
Because it doesn't activate MC3R/MC4R, Melanotan I lacks the nausea, flushing, and spontaneous erection side effects commonly reported with Melanotan II. Implant-site reactions and headache are the most commonly reported effects in the Scenesse trial program. Active malignancy is a precautionary contraindication given the melanocyte-stimulating mechanism.
Melanotan I (Afamelanotide) Research Evidence
FDA-Approved for a Rare Disease
Afamelanotide was FDA-approved in 2019 under the brand Scenesse — a subcutaneous implant — specifically for erythropoietic protoporphyria, where it meaningfully increases pain-free light exposure time for patients. Separately, a 2015 trial (Lim et al., JAMA Dermatology, n=55) found monthly afamelanotide added to narrowband UVB phototherapy improved vitiligo repigmentation compared to phototherapy alone, with a larger effect in darker skin tones.
Regulatory and Legal Status
Melanotan I is FDA-approved as Scenesse specifically for EPP. Use for general tanning or cosmetic purposes is not what was tested or approved — that use is off-label at best, and unapproved research-chemical use in that context should be treated as RUO. Researchers and users should verify the legal status of non-EPP afamelanotide use in their jurisdiction.
Melanotan I (Afamelanotide) Stacking and Combinations
Standalone Photoprotection Use
Melanotan I is used as a standalone photoprotection/pigmentation compound. Unlike Melanotan II, it isn't typically discussed as part of a sexual-health or appetite-related stacking protocol, since it lacks those receptor targets entirely.
Melanotan I (Afamelanotide) Pharmacokinetics
Short Circulating Half-Life, Implant Extends Duration
Free afamelanotide has a short plasma half-life of roughly 30-50 minutes; the FDA-approved implant achieves its roughly month-long duration of effect through sustained-release delivery from the implant itself, not from the peptide's intrinsic pharmacokinetics.
Contraindications
- pregnancy
- active malignancy
- known photosensitizing conditions requiring specialist oversight
Trials and reviews
- Lim vitiligo trialJAMA Dermatology2015
Monthly afamelanotide + NB-UVB repigmented more than phototherapy alone (n=55)
Frequently asked questions
What is a typical Melanotan I (Afamelanotide) dose?
Published research protocols report 16 mg implant, 1x monthly. This is the range described in the literature, not a recommendation.
What is the half-life of Melanotan I (Afamelanotide)?
~30-50 minutes.
Is Melanotan I (Afamelanotide) backed by strong evidence?
Melanotan I (Afamelanotide) carries a REGEN research grade of B. REGEN Research Tier B — a real FDA approval (Scenesse), but for a narrow rare-disease indication.
How is Melanotan I (Afamelanotide) administered?
Routes reported in the literature: subcutaneous.
Who should avoid Melanotan I (Afamelanotide)?
Contraindications noted in the literature include pregnancy, active malignancy, known photosensitizing conditions requiring specialist oversight.
References
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo · Lim HW, et al. · 2015